Meenadchi Chelvakumar Chelvakumar, MD
Family Practice · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 22
- 5 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
22 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chelvakumar’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
22 of 22 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| AARP Medicare Advantage from UHC CA-10 (HMO-POS) | UnitedHealthcare | Listed, may be out of date | Jun 10, 2026 |
California Medical Board record
Licence A144529 · Current
Licensed to practise in California · since 2016 · expires 2028-05-31 · University of Illinois College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$10,671
Medicare paid this office $10,671 for 77 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 64 | $6,359 | $49 |
| Telephone medical discussion with physician, 11-20 minutes | 19 | $2,078 | $80 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 27 | $1,422 | $53 |
Who their Medicare patients are
77 Original Medicare patients in 2024. Average age 70 · Women 62% · Also on Medicaid 17% · Health risk score 1.10. At or below the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 45% · Diabetes 30% · Coronary heart disease 18% · Chronic kidney disease 18% · Atrial fibrillation 16% · Depression 16%.
The office billed $64,226, Medicare allowed $15,377 and paid $10,671; for 198 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 77 | 198 | 70 | 1.10 | $64,226 | $10,671 |
| 2023 | 77 | 201 | 73 | 1.22 | $53,792 | $10,245 |
| 2022 | 67 | 179 | 73 | 1.18 | $47,815 | $8,527 |
| 2021 | 47 | 147 | 73 | 1.26 | $38,841 | $7,619 |
| 2020 | 36 | 92 | 73 | 1.40 | $20,191 | $4,000 |
| 2019 | 42 | 95 | 73 | 1.27 | $6,360 | $4,344 |
| 2018 | 28 | 35 | 73 | 1.37 | $2,175 | $1,536 |
| 2017 | 12 | 12 | 71 | 1.12 | $1,104 | $548 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Short return visit (20+ min) | 64 | $6,747 | $48 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 18 | $1,172 | $65 |
| Telephone medical discussion with physician, 11-20 minutes | 16 | $1,056 | $48 |
2022: 2 services
| Short return visit (20+ min) | 55 | $5,809 | $51 |
| Telephone medical discussion with physician, 5-10 minutes | 16 | $739 | $30 |
2021: 2 services
| Short return visit (20+ min) | 42 | $5,139 | $54 |
| Telephone medical discussion with physician, 5-10 minutes | 15 | $926 | $33 |
2020: 1 service
| Short return visit (20+ min) | 28 | $2,546 | $45 |
2019: 1 service
| Short return visit (20+ min) | 41 | $3,461 | $42 |
2018: 1 service
| Short return visit (20+ min) | 26 | $1,420 | $44 |
2017: 1 service
| Short return visit (20+ min) | 12 | $548 | $46 |
Medicaid work
$220,668 in 2024
Medicaid paid $220,668 for 4,365 billed services this clinician did in 2024, up to 81 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 544 | $208,636 |
| Short return visit (20+ min) | 1,123 | $10,368 |
| Screening for depression is documented as negative, a follow-up plan is not required | 268 | $845 |
| Alcohol and/or drug screening | 121 | $410 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 186 | $397 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 233 | $12 |
| BODY MASS INDEX DOCD | 633 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 544 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 20 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 492 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 201 | $0 |
| 2024 | 4,365 | 11 | 81 | $220,668 |
| 2023 | 4,775 | 11 | 111 | $283,719 |
| 2022 | 4,134 | 11 | 100 | $247,999 |
| 2021 | 4,667 | 11 | 118 | $361,042 |
| 2020 | 1,385 | 7 | 69 | $139,793 |
| 2019 | 1,351 | 5 | 48 | $67,322 |
| 2018 | 130 | 2 | 38 | $13,008 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 762 | $279,511 |
| Short return visit (20+ min) | 1,489 | $3,453 |
| Screening for depression is documented as negative, a follow-up plan is not required | 248 | $405 |
| Alcohol and/or drug screening | 157 | $205 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 285 | $142 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 189 | $4 |
| BODY MASS INDEX DOCD | 579 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 455 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 29 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 403 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 179 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 676 | $242,939 |
| Short return visit (20+ min) | 1,338 | $3,785 |
| Screening for depression is documented as negative, a follow-up plan is not required | 234 | $430 |
| Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use | 41 | $385 |
| Alcohol and/or drug screening | 194 | $216 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 266 | $189 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 174 | $55 |
| BODY MASS INDEX DOCD | 424 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 362 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 322 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 103 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 998 | $354,209 |
| Short return visit (20+ min) | 1,642 | $5,720 |
| Screening for depression is documented as negative, a follow-up plan is not required | 260 | $510 |
| Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use | 46 | $266 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 240 | $149 |
| Alcohol and/or drug screening | 159 | $144 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 288 | $44 |
| BODY MASS INDEX DOCD | 721 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 147 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 130 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 36 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 499 | $137,724 |
| Short return visit (20+ min) | 444 | $1,774 |
| Short return visit | 207 | $188 |
| Screening for depression is documented as negative, a follow-up plan is not required | 42 | $67 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 39 | $26 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 113 | $15 |
| BODY MASS INDEX DOCD | 41 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 519 | $64,845 |
| Short return visit | 536 | $2,251 |
| Short return visit (20+ min) | 13 | $102 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 219 | $100 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 64 | $25 |
2018
| Clinic visit/encounter, all-inclusive | 108 | $13,008 |
| Short return visit | 22 | $0 |
Drugs they prescribed that Part D paid
$150,804
Pharmacies billed $150,804 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (20 of 1,062) in 2024. Above the middle of the specialty; the typical family practice clinician is at 2%.
903 generic and fewer than 11 brand-name prescriptions · $150,804 in drug cost · 23 antibiotic prescriptions to 21 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jardiance | 33 | $51,499 | $1,561 |
| Eliquis | 24 | $34,218 | $1,426 |
| Mounjaro | 12 | $16,280 | $1,357 |
| Atorvastatin | 112 | $932 | $8 |
| Gabapentin | 40 | $540 | $13 |
See all 27 drugs
| Jardiance | 33 | $51,499 | $1,561 |
| Eliquis | 24 | $34,218 | $1,426 |
| Mounjaro | 12 | $16,280 | $1,357 |
| Atorvastatin | 112 | $932 | $8 |
| Gabapentin | 40 | $540 | $13 |
| Levothyroxine | 35 | $512 | $15 |
| Rosuvastatin | 23 | $495 | $22 |
| Metformin | 40 | $473 | $12 |
| Pantoprazole | 13 | $443 | $34 |
| Losartan | 21 | $415 | $20 |
| Sulfasalazine | 14 | $411 | $29 |
| Albuterol Sulfate Hfa | 13 | $398 | $31 |
| Lisinopril | 63 | $355 | $6 |
| Allopurinol | 15 | $328 | $22 |
| Finasteride | 19 | $304 | $16 |
| Amlodipine Besylate | 41 | $286 | $7 |
| Simvastatin | 11 | $262 | $24 |
| Cyclobenzaprine | 14 | $248 | $18 |
| Trazodone | 13 | $226 | $17 |
| Sertraline | 19 | $223 | $12 |
| Quetiapine | 14 | $156 | $11 |
| Alendronate | 25 | $148 | $6 |
| Fluticasone Propionate | 15 | $136 | $9 |
| Hydrochlorothiazide | 20 | $98 | $5 |
| Meloxicam | 24 | $94 | $4 |
| Omeprazole | 13 | $87 | $7 |
| Triamcinolone Acetonide | 11 | $67 | $6 |
Year by year
| 2024 | 1,062 | 140 | 2% (20) | None | $150,804 |
| 2023 | 955 | 167 | 3% (27) | None | $109,564 |
| 2022 | 897 | 153 | 1% (13) | None | $73,446 |
| 2021 | 723 | 104 | 2% (14) | None | $59,766 |
| 2020 | 567 | 88 | 3% (15) | None | $25,947 |
| 2019 | 340 | 74 | 3% (11) | None | $16,023 |
| 2018 | 41 | 17 | None | None | $1,974 |
| 2017 | 13 | None | 0% (0) | None | $488 |
| 2016 | 251 | 42 | None | 14% | $5,620 |
| 2015 | 208 | 39 | 11% (22) | 14% | $5,018 |
| 2014 | 130 | 31 | 9% (11) | None | $4,069 |
| 2013 | 21 | 11 | None | None | $517 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 24 drugs
| Eliquis | 21 | $26,781 | $1,275 |
| Atorvastatin | 124 | $2,193 | $18 |
| Diclofenac | 14 | $1,035 | $74 |
| Gabapentin | 31 | $1,003 | $32 |
| Levothyroxine | 44 | $781 | $18 |
| Losartan | 22 | $762 | $35 |
| Amlodipine Besylate | 43 | $734 | $17 |
| Albuterol Sulfate Hfa | 15 | $722 | $48 |
| Metformin | 45 | $636 | $14 |
| Propranolol | 14 | $535 | $38 |
| Sulfasalazine | 12 | $521 | $43 |
| Tamsulosin | 14 | $492 | $35 |
| Lisinopril | 35 | $488 | $14 |
| Trazodone | 14 | $470 | $34 |
| Metoprolol | 12 | $376 | $31 |
| Hydrochlorothiazide | 29 | $373 | $13 |
| Alendronate | 19 | $365 | $19 |
| Simvastatin | 20 | $298 | $15 |
| Rosuvastatin | 11 | $271 | $25 |
| Pantoprazole | 12 | $219 | $18 |
| Allopurinol | 11 | $188 | $17 |
| Fluticasone Propionate | 12 | $180 | $15 |
| Omeprazole | 14 | $111 | $8 |
| Meloxicam | 11 | $70 | $6 |
2022: 24 drugs
| Duloxetine | 15 | $1,953 | $130 |
| Atorvastatin | 95 | $1,337 | $14 |
| Diclofenac | 31 | $1,179 | $38 |
| Quetiapine | 15 | $1,175 | $78 |
| Albuterol Sulfate Hfa | 18 | $805 | $45 |
| Losartan | 37 | $571 | $15 |
| Oxybutynin Chloride | 13 | $483 | $37 |
| Hydrochlorothiazide | 56 | $446 | $8 |
| Carbidopa-Levodopa | 13 | $440 | $34 |
| Amlodipine Besylate | 58 | $437 | $8 |
| Levothyroxine | 27 | $427 | $16 |
| Tamsulosin | 15 | $400 | $27 |
| Metoprolol | 17 | $371 | $22 |
| Famotidine | 11 | $370 | $34 |
| Lisinopril | 26 | $295 | $11 |
| Metformin | 32 | $285 | $9 |
| Omeprazole | 21 | $253 | $12 |
| Gabapentin | 16 | $219 | $14 |
| Finasteride | 11 | $201 | $18 |
| Metoprolol | 12 | $187 | $16 |
| Simvastatin | 26 | $185 | $7 |
| Carvedilol | 14 | $143 | $10 |
| Cyclobenzaprine | 11 | $137 | $12 |
| Meloxicam | 12 | $48 | $4 |
2021: 17 drugs
| Oxycodone-Acetaminophen | 13 | $1,553 | $119 |
| Diclofenac | 38 | $1,398 | $37 |
| Atorvastatin | 80 | $1,381 | $17 |
| Albuterol Sulfate Hfa | 14 | $659 | $47 |
| Gabapentin | 19 | $428 | $23 |
| Metoprolol | 20 | $419 | $21 |
| Amlodipine Besylate | 49 | $404 | $8 |
| Levothyroxine | 17 | $400 | $24 |
| Propranolol | 11 | $343 | $31 |
| Losartan | 27 | $335 | $12 |
| Lisinopril | 24 | $176 | $7 |
| Omeprazole | 11 | $172 | $16 |
| Metformin | 25 | $165 | $7 |
| Glipizide | 13 | $142 | $11 |
| Hydrochlorothiazide | 20 | $121 | $6 |
| Metoprolol | 14 | $108 | $8 |
| Furosemide | 15 | $53 | $4 |
2020: 15 drugs
| Oxycodone-Acetaminophen | 15 | $691 | $46 |
| Levothyroxine | 26 | $666 | $26 |
| Atorvastatin | 63 | $646 | $10 |
| Albuterol Sulfate Hfa | 13 | $588 | $45 |
| Gabapentin | 23 | $567 | $25 |
| Diclofenac | 15 | $494 | $33 |
| Quetiapine | 11 | $399 | $36 |
| Metoprolol | 15 | $392 | $26 |
| Losartan | 30 | $346 | $12 |
| Hydrochlorothiazide | 13 | $166 | $13 |
| Amlodipine Besylate | 29 | $159 | $5 |
| Omeprazole | 11 | $122 | $11 |
| Metformin | 19 | $112 | $6 |
| Metoprolol | 12 | $83 | $7 |
| Lisinopril | 15 | $79 | $5 |
2019: 7 drugs
| Oxycodone-Acetaminophen | 11 | $981 | $89 |
| Atorvastatin | 28 | $398 | $14 |
| Gabapentin | 16 | $391 | $24 |
| Levothyroxine | 14 | $390 | $28 |
| Amlodipine Besylate | 25 | $230 | $9 |
| Fluticasone Propionate | 13 | $194 | $15 |
| Losartan | 18 | $153 | $8 |
2016: 6 drugs
| Zetia | 13 | $1,813 | $139 |
| Amitriptyline | 14 | $151 | $11 |
| Lisinopril | 11 | $138 | $13 |
| Amlodipine Besylate | 20 | $131 | $7 |
| Fluticasone Propionate | 13 | $121 | $9 |
| Hydrochlorothiazide | 13 | $55 | $4 |
2015: 4 drugs
| Morphine Sulfate Er | 17 | $691 | $41 |
| Amlodipine Besylate | 22 | $164 | $7 |
| Lisinopril | 11 | $77 | $7 |
| Hydrochlorothiazide | 13 | $57 | $4 |
2014: 2 drugs
| Metformin | 13 | $67 | $5 |
| Losartan | 11 | $64 | $6 |
Money from drug and device companies
$117 in 2019
A payment is not proof that care is biased.
| Merck Sharp & Dohme | Gardasil | $117 | 1 payment
|
See the published payment
| Merck Sharp & Dohme | Meals · 2019-08-01 | Gardasil | $117 |
Professional record
- NPI
- 1679816854
- Licence
- CA A144529California A144529: Current · expires 2028-05-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2013-04-05
- NPI last updated
- 2024-04-17
- NPI record certified
- 2024-04-17
This is when the NPI record was last certified, not a medical board exam.